• Activation of Akt characterizes estrogen receptor positive human breast cancers which respond to anthracyclines 

      Yndestad, Synnøve; Austreid, Eilin; Svanberg, Ida; Knappskog, Stian; Lønning, Per Eystein; Eikesdal, Hans Petter (Peer reviewed; Journal article, 2017-04-17)
      Anthracyclines are key components of human breast cancer chemotherapy. Here, we explored the role of Akt signaling in anthracycline resistance. The antitumor activity of doxorubicin and Akt inhibitor A-443654 alone or ...
    • Clinical Efficacy and Safety of Bevacizumab Monotherapy in Patients with Metastatic Melanoma: Predictive Importance of Induced Early Hypertension 

      Schuster, Cornelia; Eikesdal, Hans Petter; Puntervoll, Hanne; Geisler, Jürgen; Geisler, Stephanie; Molven, Anders; Akslen, Lars A. (Peer reviewed; Journal article, 2012-06-15)
      Background: VEGF driven angiogenesis plays a key role in cancer progression. We determined the clinical efficacy of bevacizumab monotherapy in patients with metastatic melanoma. Methods and Findings: Thirty-five patients ...
    • Clonal evolution in primary breast cancers under sequential epirubicin and docetaxel monotherapy 

      Venizelos, Andreas; Engebrethsen, Christina; Deng, Wei; Geisler, Jürgen; Geisler, Stephanie; Iversen, Gjertrud Titlestad; Aas, Turid; Aase, Hildegunn Siv; Seyedzadeh, Manouchehr; Steinskog, Eli Sihn Samdal; Myklebost, Ola; Nakken, Sigve; Vodák, Daniel; Hovig, Eivind; Meza, Leonardo Zepeda; Lønning, Per Eystein; Knappskog, Stian; Eikesdal, Hans Petter (Journal article; Peer reviewed, 2022)
      Background Subclonal evolution during primary breast cancer treatment is largely unexplored. We aimed to assess the dynamic changes in subclonal composition of treatment-naïve breast cancers during neoadjuvant ...
    • Constitutional BRCA1 methylation and risk of incident triple-negative breast cancer and high-grade serous ovarian cancer 

      Lønning, Per Eystein; Nikolaienko, Oleksii; Pan, Kathy; Kurian, Allison W.; Eikesdal, Hans Petter; Pettinger, Mary; Anderson, Garnet L.; Prentice, Ross L.; Chlebowski, Rowan T.; Knappskog, Stian (Journal article; Peer reviewed, 2022)
      Importance About 25% of all triple-negative breast cancers (TNBCs) and 10% to 20% of high-grade serous ovarian cancers (HGSOCs) harbor BRCA1 promoter methylation. While constitutional BRCA1 promoter methylation has been ...
    • DNA methylation changes in response to neoadjuvant chemotherapy are associated with breast cancer survival 

      Pedersen, Christine Aaserød; Cao, Maria Dung; Fleischer, Thomas; Rye, Morten Beck; Knappskog, Stian; Eikesdal, Hans Petter; Lønning, Per Eystein; Tost, Jörg; Kristensen, Vessela N.; Tessem, May-Britt; Giskeødegård, Guro F.; Bathen, Tone Frost (Journal article; Peer reviewed, 2022)
      Background: Locally advanced breast cancer is a heterogeneous disease with respect to response to neoadjuvant chemotherapy (NACT) and survival. It is currently not possible to accurately predict who will benefit from the ...
    • High PTEN gene expression is a negative prognostic marker in human primary breast cancers with preserved p53 function 

      Yndestad, Synnøve; Austreid, Eilin; Knappskog, Stian; Chrisanthar, Ranjan; Lilleng, Peer Kåre; Lønning, Per Eystein; Eikesdal, Hans Petter (Peer reviewed; Journal article, 2017)
      Purpose: PTEN is an important tumor suppressor in breast cancer. Here, we examined the prognostic and predictive value of PTEN and PTEN pseudogene (PTENP1) gene expression in patients with locally advanced breast cancer ...
    • Impaired lymphatic function accelerates cancer growth 

      Steinskog, Eli Sihn Samdal; Sagstad, Solfrid Johanne; Wagner, Marek; Karlsen, Tine Veronica; Yang, Ning; Markhus, Carl Erik Nordvik; Yndestad, Synnøve; Wiig, Helge; Eikesdal, Hans Petter (Peer reviewed; Journal article, 2016-06-13)
      Increased lymphangiogenesis is a common feature of cancer development and progression, yet the influence of impaired lymphangiogenesis on tumor growth is elusive. C3HBA breast cancer and KHT-1 sarcoma cell lines were ...
    • Mutational Signature 3 Detected from Clinical Panel Sequencing is Associated with Responses to Olaparib in Breast and Ovarian Cancers 

      Batalini, Felipe; Gulhan, Doga C.; Mao, Victor; Tran, Antuan; Polak, Madeline; Xiong, Niya; Tayob, Nabihah; Tung, Nadine M.; Winer, Eric P.; Mayer, Erica L.; Knappskog, Stian; Lønning, Per Eystein; Matulonis, Ursula A.; Konstantinopoulos, Panagiotis A.; Solit, David B.; Won, Helen; Eikesdal, Hans Petter; Park, Peter J.; Wulf, Gerburg M. (Journal article; Peer reviewed, 2022)
      Purpose: The identification of patients with homologous recombination deficiency (HRD) beyond BRCA1/2 mutations is an urgent task, as they may benefit from PARP inhibitors. We have previously developed a method to detect ...
    • Olaparib monotherapy as primary treatment in unselected triple negative breast cancer 

      Eikesdal, Hans Petter; Yndestad, Synnøve; Elzawahry, Asmaa; Llop-Guevara, Alba; Gilje, Bjørnar; Blix, Egil Støre; Espelid, Helge; Lundgren, Steinar; Geisler, Jürgen; Vagstad, Geirfinn; Venizelos, Andreas; Minsaas, Laura; Leirvaag, Beryl; Gudlaugsson, Einar; Vintermyr, Olav Karsten; Aase, Hildegunn Siv; Aas, Turid; Balmaña, Judith; Serra, Violeta; Janssen, Emiel; Knappskog, Stian; Lønning, Per Eystein (Journal article; Peer reviewed, 2020)
      Background The antitumor efficacy of PARP inhibitors (PARPi) for breast cancer patients harboring germline BRCA1/2 (gBRCA1/2) mutations is well established. While PARPi monotherapy was ineffective in patients with metastatic ...
    • PARP-inhibition reprograms macrophages toward an anti-tumor phenotype 

      Wang, Lin; Wang, Dan; Sonzogni, Olmo; Ke, Shizhong; Wang, Qi; Thavamani, Abhishek; Batalini, Felipe; Stopka, Sylwia A.; Regan, Michael S.; Vandal, Steven; Tian, Shengya; Pinto, Jocelin; Cyr, Andrew M.; Bret-Mounet, Vanessa C.; Baquer, Gerard; Eikesdal, Hans Petter; Yuan, Min; Asara, John M.; Heng, Yujing J.; Bai, Peter; Agar, Nathalie Y.R.; Wulf, Gerburg M. (Journal article; Peer reviewed, 2022)
      Poly(ADP)ribosylation inhibitors (PARPis) are toxic to cancer cells with homologous recombination (HR) deficiency but not to HR-proficient cells in the tumor microenvironment (TME), including tumor-associated macrophages ...
    • Prenatal BRCA1 epimutations contribute significantly to triple-negative breast cancer development 

      Nikolaienko, Oleksii; Eikesdal, Hans Petter; Berge, Elisabet Ognedal; Gilje, Bjørnar; Lundgren, Steinar; Blix, Egil Støre; Espelid, Helge; Geisler, Jürgen; Geisler, Stephanie; Janssen, Emiel; Yndestad, Synnøve; Minsaas, Laura; Leirvaag, Beryl; Lillestøl, Reidun Kristine; Knappskog, Stian; Lønning, Per Eystein (Journal article; Peer reviewed, 2023)
      Background Normal cell BRCA1 epimutations have been associated with increased risk of triple-negative breast cancer (TNBC). However, the fraction of TNBCs that may have BRCA1 epimutations as their underlying cause is ...
    • Semi-automatic segmentation from intrinsically-registered 18F-FDG-PET/MRI for treatment response assessment in a breast cancer cohort: comparison to manual DCE-MRI 

      Andreassen, Maren Marie Sjaastad; Goa, Pål Erik; Sjøbakk, Torill Eidhammer; Hedayati, Roja; Eikesdal, Hans Petter; Deng, Callie; Østlie, Agnes; Lundgren, Steinar; Bathen, Tone Frost; Jerome, Neil Peter (Peer reviewed; Journal article, 2019-09-27)
      Objectives: To investigate the reliability of simultaneous positron emission tomography and magnetic resonance imaging (PET/MRI)-derived biomarkers using semi-automated Gaussian mixture model (GMM) segmentation on PET ...
    • TP53 status predicts long-term survival in locally advanced breast cancer after primary chemotherapy 

      Eikesdal, Hans Petter; Knappskog, Stian; Aas, Turid; Lønning, Per Eystein (Peer reviewed; Journal article, 2014-10)
      Background: Before the advent of neoadjuvant chemotherapy, radiotherapy and surgery alone were associated with a high risk of uncontrolled locoregional relapses in locally advanced breast cancer (LABC). Material and methods: ...